Novo Nordisk Faces New Legal Challenge Over Ozempic's Link to Irreversible Eye Condition

Event summary

  • Parker Waichman LLP filed a lawsuit on behalf of an Ohio resident who developed NAION after taking Ozempic, adding to multiple ongoing cases against Novo Nordisk.
  • The lawsuit (Morris v. Novo Nordisk Inc., et al.) was filed on June 24, 2026, in the U.S. District Court (Docket No: 2:26-cv-04358).
  • Studies from JAMA Ophthalmology and Harvard's Mass Eye and Ear Institute found a significant link between semaglutide (Ozempic/Wegovy) and NAION, with non-diabetic users facing a sevenfold increased risk.
  • Novo Nordisk continues to downplay the risks despite growing evidence, failing to include adequate warnings about permanent blindness.

The big picture

Novo Nordisk's blockbuster weight-loss and diabetes drugs, Ozempic and Wegovy, face increasing legal and regulatory risks due to their potential link to NAION. The company's failure to adequately warn consumers and medical professionals about these risks could lead to significant financial and reputational damage. This development comes as GLP-1 receptor agonists continue to dominate the obesity and diabetes treatment markets, raising questions about long-term safety and regulatory oversight.

What we're watching

Regulatory Scrutiny
How regulatory bodies will respond to the growing evidence linking Ozempic and Wegovy to NAION, potentially leading to stricter warnings or recalls.
Legal Exposure
The pace at which additional lawsuits are filed against Novo Nordisk, and whether the company will face significant financial penalties or settlements.
Market Impact
Whether these legal challenges will affect Ozempic and Wegovy's market dominance in the GLP-1 receptor agonist space, particularly as competitors develop similar drugs.

Related topics

Pharmaceuticals